Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Oct 9;635(8038):462–471. doi: 10.1038/s41586-024-07943-7

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2024

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.

PMC Copyright notice

Fig. 1 — a, PFS, OS and ORR with pemetrexed, carboplatin or cisplatin and pembrolizumab (PCP) in patients with STK11^MUT (n = 119) versus STK11^WT (n = 320) (top) or with KEAP1^MUT (n = 42) versus KEAP1^WT (n = 103) (bottom) advanced nsNSCLC. The comparison of ORR (partial response (PR)/complete response (CR)) in patients with STK11^MUT versus STK11^WT and KEAP1^MUT versus KEAP1^WT tumours was based on the chi-squared test. Log-rank test was used for comparisons of PFS and OS. Multivariate (MV) HRs (adjusted for age, ECOG performance status and presence of brain metastases) and 95% CIs were estimated using a Cox proportional hazards model. P ≤ 0.05 was considered statistically significant. NS, not significant. b, Prevalence of individual and combined STK11 and KEAP1 alterations in advanced LUAD (left; n = 8,592) or KRAS-mutated LUAD (right; n = 3,224) from the Foundation Medicine (FMI) database. c, TMB in single and double STK11^MUT and/or KEAP1^MUT and STK11^WT/KEAP1^WT LUAD in the FMI dataset. Median TMB (table insert) and fraction of tumours with a TMB of 10 or more mutations per Mb or fewer than 10 mutations per Mb (bar chart) in each subgroup are indicated. d, PD-L1 tumour proportion score (TPS) in single and double STK11^MUT and/or KEAP1^MUT and STK11^WT/KEAP1^WT LUAD in the FMI dataset (n = 8,836). The chi-squared test from a 2 × 4 contingency table was used to compare the distribution of PD-L1-positive (TPS ≥ 1%) and -negative (TPS < 1%) tumours across the four oncogenotypes. e, Volcano plot of enriched somatic genomic alterations in PD-L1-negative (TPS < 1%, grey circles) versus PD-L1-positive (TPS ≥ 1%, red circles) LUAD with an intermediate or high TMB (TMB^I/H; six or more mutations per Mb; n = 4,672). The size of individual circles is proportional to the prevalence of the corresponding alteration. Two-sided Fisher’s exact test was used for statistical comparisons and statistical significance was established at false discovery rate (FDR)-adjusted P ≤ 0.05.